Skip to content

Patient Response to Spinal Manipulation

Patient Response to Spinal Manipulation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01670292
Acronym
PRiSM
Enrollment
82
Registered
2012-08-22
Start date
2012-09-30
Completion date
2014-06-30
Last updated
2017-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Keywords

Low Back Pain

Brief summary

This is a biomechanical study which is Project 1 in the Developmental Center for Clinical and Translational Research in Chiropractic (DCRC I) (NIH/NCCAM grant 1 U19 AT004663-01; principal investigator Christine Goertz, DC, PhD). This study is designed to monitor both physiological and patient self-report outcome variables. In addition, as there is little quantitative information on Spinal Manipulation Technique procedures reported in clinical trials, the study is designed to collect preliminary kinetic measures of the spinal manipulation technique delivery (i.e. force-time profiles).

Detailed description

Participants with narrowly defined chronic low back pain will be included in this study. Each participant will be treated 12 times over the course of 6 weeks. The following data will be collected: participant characteristics that may predict outcome or be modifiers of force used by provider (gender, age, height, weight, and Body Mass Index); spinal segment load during the pre-load and thrusting phases (force and moment in the pre-load phase, peak load, and loading rate); physiological measures (posterior-anterior global stiffness and flexion-relaxation); patient-centered outcomes of back pain and function; and adverse events. Study participants (n= 80) will be recruited from the Quad Cities metro area. A team of experienced chiropractic clinicians working at the Palmer Center for Chiropractic Research will treat study participants. Each of the study participants will receive 2 High Velocity Low Amplitude Spinal Manipulation treatment visits per week over a 6 week period. The physiological assessments will be performed immediately before and after Spinal Manipulation delivery during treatment visits 1, 5 & 12 (6 sets of assessments in total). During these same treatment visits, we will also capture the kinetic measures during Spinal Manipulation delivery for spinal segment load analysis. Participant patient-centered outcomes will be measured at baseline 1, and treatment visits 6 and 13. For simplicity, data collection time points will be named as baseline, after 2 weeks, and after 6 weeks.

Interventions

OTHERHVLA-SM

High Velocity Low Amplitude Spinal Manipulation

Sponsors

University of Iowa
CollaboratorOTHER
National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH
Palmer College of Chiropractic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* NRS score, AVERAGE within the past 24 hours * Must be ≥4 at the phone screen or baseline 1 visit * Must be ≥2 at phone screen, baseline 1 and baseline 2 visits * Roland Morris Disability ≥6 * Age 21-65 * Signed informed consent document * Chronic (12+ weeks) low back pain

Exclusion criteria

* Compliance concerns * No manipulable lesion in L1-L5 or SI joints * The absence of typical palpatory characteristics as well as the absence of a global assessment that would indicate that spinal manipulation is likely to generate a positive therapeutic effect, even without the presence of standard palpatory findings * Ongoing treatment for low back pain by outside provider * Comorbid conditions * Serious concomitant illness * Inflammatory or destructive spinal tissue change * Ankylosing Spondylytis * Fibromyalgia * Rheumatoid Arthritis * Confirmed or suspected disc herniation with neurological signs * Neuromuscular disease (e.g. Parkinson's, Muscular Dystrophy, Cerebral Palsy, or Myasthenia gravis * Spinal surgery \<6 months * Suspicion of drug or alcohol dependence or abuse * Uncontrolled hypertension * Lower extremity peripheral arterial disease * Undetermined, infections or visceral source of low back pain * Other comorbid conditions prohibiting treatment and/or testing * Safety concerns * Bleeding disorders * Contraindications to High Velocity Low Amplitude Spinal Manipulation * Inability to tolerate or obtain positon for flexion-relaxation test without condition aggravation * Inability to tolerate or perform/receive any study procedure without condition aggravation * Quebec Task Force (QTF) criterion 4-11: * QTF 4: Pain + radiation to upper/lower limb with neurologic signs * QTF 5: Presumptive compression of a spinal nerve root on a simple roentgenogram * QTF 6: Compression of a spinal nerve root confirmed by specific imaging techniques * QTF 7: Spinal Stenosis * QTF 8: Postsurgical status, 1-6 months after intervention * QTF 9: Postsurgical status, \>6 months after intervention * QTF 10: Chronic pain syndrome * QTF 11: Other diagnoses * Pregnancy * Pacemaker or defibrillator * Inability to read or verbally comprehend English * Joint replacement * Use of spinal manipulation within past 4 weeks * Sensitivity to adhesive * Diagnostic procedures other than x-ray/UA necessary * BDI-II ≥29 * Retention of legal advice and open or pending case related to low back pain * BMI ≥40 * Unwilling to have low back and wrist shaved * Moving from Quad Cities area within next 8 weeks * Unwilling to postpone treatments for low back pain from another provider * Seeking or receiving compensation for any disability

Design outcomes

Primary

MeasureTime frameDescription
Patient-Centered Outcome Measurement Mean Change After 6 Weeks (VAS, RMDQ)Baseline to 6 weeksVAS - Visual Analog Scale - Scale: 0-100 mm (anchors: 0 mm = No Pain, 100 mm = Worst Imaginable Pain). VAS Interpretation: A higher score indicates greater pain intensity. In this study, improvement of 30% from the baseline value was considered clinically significant. RMDQ - Roland Morris disability questionnaire - Scale: 0 (no disability) to 24 (maximum disability). RMDQ Interpretation: Greater levels of disability are reflected by higher scores. In this study, improvement of 30% from the baseline value was considered clinically significant.
Lumbar-spine Stiffness (LSS)Baseline, 2 weeks, 6 weeksLSS\* contains 5 variables: global stiffness (GS, unit: Newton/mm) at L3 from 1) hand palpation 2) a hand-held device & 3) an automated indenter device; global stiffness variation (GSV, unit: Newton/mm) between GS from L1 to L5 from 4) hand palpation & 5) a hand-held device. \*LSS Interpretation: The values of the outcome depend on testing procedure, instruction to participants, and equipment. Currently there is no consensus regarding what value is high than normal, normal, lower than normal.
Lumbar-spine Stiffness (LSS) - Normalized Global Stiffness VariationBaseline, 2 weeks, 6 weeksLSS contains 2 variables: Palpatory and Handheld device - normalized global stiffness variation (nGSV, unitless). LSS Interpretation: The values of the outcome depend on testing procedure, instruction to participants, and equipment. Currently there is no consensus regarding what value is higher than normal, normal, lower than normal.
Flexion-Relaxation Ratio (FRR)Baseline, 2 weeks, 6 weeksFRR contains 4 variables, which are the average right and left back muscle FRR obtained using 1) maximum EMG during flexion, and 2) maximum EMG during extension to normalize EMG during full flexion; and asymmetry between the right and left back muscle FRRs using 3) maximum EMG during flexion, and 4) maximum EMG during extension to normalize EMG during full flexion FRR Interpretation: The values of the outcome depend on testing procedure, instruction to participants, and equipment. Currently there is no consensus regarding what value is high than normal, normal, lower than normal.

Secondary

MeasureTime frameDescription
PROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleBaseline, 2 weeks, 6 weeks1\) The questionnaire contains 7 PROMIS-29 specific items: Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction with Participation in Social Role (anchors: 1= 'Not at all', 5= 'Very much', higher score is worse). Each PROMIS-29 specific item is reported in raw score (4-20) and scored in T-score (T), which rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10 for a population. On the T-score metric & interpretation: * A score of 40 is one SD lower than the mean of the reference population. * A score of 60 is one SD higher than the mean of the reference population. * For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured.
Kinetic Measure - Spinal Segment Load (SSL) Force6 weeksSSL\* contains variables: maximum amplitude (Newton) during preload and peak thrust force in anterior-posterior (X), side-to-side (Y), head-to-toe direction (Z) and combined force (C). \*Interpretation: the purpose of the outcomes is to quantify force-time profile of SM. The values of the outcome depend on the doctor who delivers SM, location and direction of SM, participant body position, and equipment. Currently there is no consensus regarding what value is higher than normal, normal, or lower than normal. Sign convention: because patient position would affect the sign of some measurements, the right side up position was used as the reference position (i.e., the affected measurements assessed in the left side up position had their sign inverted) in order to calculate mean and SD. The value reported is the change from baseline to week 6.
BothersomenessBaseline, 2 weeks, 6 weeksQuestion asked of participants: During the past week, how bothersome have each of the following symptoms been? The bothersomeness questionnaire contains two items: a) low back pain & b) leg pain (sciatica). Scale: 0-10 (anchors: 0 = Not at all bothersome, 10 = Extremely bothersome)
PROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: Global Item, Pain NRSBaseline, 2 weeks, 6 weeks1\) The PROMIS questionnaire contains 1 PROMIS global item: Pain NRS, Scale: 0-10 (anchors: 0 = No Pain, 10 = Worst Imaginable Pain, higher score is worse). The PROMIS global item is not scored but reported in raw score.
Kinetic Measure - Spinal Segment Load (SSL) Moment6 weeksSSL\* contains variables: maximum amplitude (Newton\*Meter for moment) during preload and peak thrust force in anterior-posterior (X), side-to-side (Y), head-to-toe direction (Z) and combined force (C). \*Interpretation: the purpose of the outcomes is to quantify force-time profile of SM. The values of the outcome depend on the doctor who delivers SM, location and direction of SM, participant body position, and equipment. Currently there is no consensus regarding what value is higher than normal, normal, or lower than normal. Sign convention: because patient position would affect the sign of some measurements, the right side up position was used as the reference position (i.e., the affected measurements assessed in the left side up position had their sign inverted) in order to calculate mean and SD. The value reported is the change from baseline to week 6.
Kinetic Measure - Spinal Segment Load (SSL) Rate of Loading for Force6 weeksSSL\* contains variables: rate of loading for force in anterior-posterior (X), side-to-side (Y), head-to-toe direction (Z) and combined force (C). \*Interpretation: the purpose of the outcomes is to quantify force-time profile of SM. The values of the outcome depend on the doctor who delivers SM, location and direction of SM, participant body position, and equipment. Currently there is no consensus regarding what value is higher than normal, normal, or lower than normal. Sign convention: because patient position would affect the sign of some measurements, the right side up position was used as the reference position (i.e., the affected measurements assessed in the left side up position had their sign inverted) in order to calculate mean and SD. The value reported is the change from baseline to week 6.
Kinetic Measure - Spinal Segment Load (SSL) Rate of Loading for Moment6 weeksSSL\* contains variables: rate of loading for moment in anterior-posterior (X), side-to-side (Y), head-to-toe direction (Z) and combined force (C). \*Interpretation: the purpose of the outcomes is to quantify force-time profile of SM. The values of the outcome depend on the doctor who delivers SM, location and direction of SM, participant body position, and equipment. Currently there is no consensus regarding what value is higher than normal, normal, or lower than normal. Sign convention: because patient position would affect the sign of some measurements, the right side up position was used as the reference position (i.e., the affected measurements assessed in the left side up position had their sign inverted) in order to calculate mean and SD. The value reported is the change from baseline to week 6.

Countries

United States

Participant flow

Participants by arm

ArmCount
Experimental: HVLA-SM
Experimental High Velocity Low Amplitude Spinal Manipulation HVLA-SM: High Velocity Low Amplitude Spinal Manipulation
82
Total82

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up14

Baseline characteristics

CharacteristicExperimental: HVLA-SM
Age, Continuous44.9 years
STANDARD_DEVIATION 10.6
Baseline Patient-Centered Outcome Measures
RMDQ
9.5 units on a scale
STANDARD_DEVIATION 4.3
Baseline Patient-Centered Outcome Measures
VAS
46.1 units on a scale
STANDARD_DEVIATION 18.1
Sex: Female, Male
Female
39 Participants
Sex: Female, Male
Male
43 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 82
other
Total, other adverse events
74 / 82
serious
Total, serious adverse events
0 / 82

Outcome results

Primary

Flexion-Relaxation Ratio (FRR)

FRR contains 4 variables, which are the average right and left back muscle FRR obtained using 1) maximum EMG during flexion, and 2) maximum EMG during extension to normalize EMG during full flexion; and asymmetry between the right and left back muscle FRRs using 3) maximum EMG during flexion, and 4) maximum EMG during extension to normalize EMG during full flexion FRR Interpretation: The values of the outcome depend on testing procedure, instruction to participants, and equipment. Currently there is no consensus regarding what value is high than normal, normal, lower than normal.

Time frame: Baseline, 2 weeks, 6 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Experimental: HVLA-SMFlexion-Relaxation Ratio (FRR)Asymmetry in flexion FRR1.5 ratioStandard Deviation 0.5
Experimental: HVLA-SMFlexion-Relaxation Ratio (FRR)Flexion FRR4.7 ratioStandard Deviation 3.7
Experimental: HVLA-SMFlexion-Relaxation Ratio (FRR)Asymmetry in extension FRR1.4 ratioStandard Deviation 0.7
Experimental: HVLA-SMFlexion-Relaxation Ratio (FRR)Extension FRR9.2 ratioStandard Deviation 9.5
HVLA-SM After 2 WeeksFlexion-Relaxation Ratio (FRR)Asymmetry in flexion FRR1.4 ratioStandard Deviation 0.5
HVLA-SM After 2 WeeksFlexion-Relaxation Ratio (FRR)Extension FRR10.4 ratioStandard Deviation 11.6
HVLA-SM After 2 WeeksFlexion-Relaxation Ratio (FRR)Flexion FRR5.8 ratioStandard Deviation 5.4
HVLA-SM After 2 WeeksFlexion-Relaxation Ratio (FRR)Asymmetry in extension FRR1.4 ratioStandard Deviation 0.4
HVLA-SM After 6 WeeksFlexion-Relaxation Ratio (FRR)Extension FRR9.4 ratioStandard Deviation 10.5
HVLA-SM After 6 WeeksFlexion-Relaxation Ratio (FRR)Flexion FRR5.5 ratioStandard Deviation 5.6
HVLA-SM After 6 WeeksFlexion-Relaxation Ratio (FRR)Asymmetry in extension FRR1.4 ratioStandard Deviation 0.5
HVLA-SM After 6 WeeksFlexion-Relaxation Ratio (FRR)Asymmetry in flexion FRR1.4 ratioStandard Deviation 0.4
Primary

Lumbar-spine Stiffness (LSS)

LSS\* contains 5 variables: global stiffness (GS, unit: Newton/mm) at L3 from 1) hand palpation 2) a hand-held device & 3) an automated indenter device; global stiffness variation (GSV, unit: Newton/mm) between GS from L1 to L5 from 4) hand palpation & 5) a hand-held device. \*LSS Interpretation: The values of the outcome depend on testing procedure, instruction to participants, and equipment. Currently there is no consensus regarding what value is high than normal, normal, lower than normal.

Time frame: Baseline, 2 weeks, 6 weeks

Population: 82, 71 and 68 participants completed at baseline, after 2 weeks and after 6 weeks, respectively. The number of observations at each of the 3 time points for individual measures is equal to or lower than these numbers due to missing data.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental: HVLA-SMLumbar-spine Stiffness (LSS)LSS - Hand-held - GSV (N/mm)2.3 N/mmStandard Deviation 1.3
Experimental: HVLA-SMLumbar-spine Stiffness (LSS)LSS - Automated - GS (N/mm) at Ant5.2 N/mmStandard Deviation 1.5
Experimental: HVLA-SMLumbar-spine Stiffness (LSS)LSS - Palpatory - GS (N/mm) at L34.8 N/mmStandard Deviation 1.8
Experimental: HVLA-SMLumbar-spine Stiffness (LSS)LSS - Hand-held - GS (N/mm) at L37.7 N/mmStandard Deviation 2.1
Experimental: HVLA-SMLumbar-spine Stiffness (LSS)LSS - Palpatory - GSV (N/mm)2.3 N/mmStandard Deviation 1.5
HVLA-SM After 2 WeeksLumbar-spine Stiffness (LSS)LSS - Palpatory - GS (N/mm) at L34.3 N/mmStandard Deviation 1.8
HVLA-SM After 2 WeeksLumbar-spine Stiffness (LSS)LSS - Hand-held - GS (N/mm) at L37.5 N/mmStandard Deviation 1.8
HVLA-SM After 2 WeeksLumbar-spine Stiffness (LSS)LSS - Automated - GS (N/mm) at Ant5.3 N/mmStandard Deviation 1.4
HVLA-SM After 2 WeeksLumbar-spine Stiffness (LSS)LSS - Hand-held - GSV (N/mm)2.1 N/mmStandard Deviation 1.1
HVLA-SM After 2 WeeksLumbar-spine Stiffness (LSS)LSS - Palpatory - GSV (N/mm)2.0 N/mmStandard Deviation 1.1
HVLA-SM After 6 WeeksLumbar-spine Stiffness (LSS)LSS - Automated - GS (N/mm) at Ant5.3 N/mmStandard Deviation 1.5
HVLA-SM After 6 WeeksLumbar-spine Stiffness (LSS)LSS - Palpatory - GS (N/mm) at L34.2 N/mmStandard Deviation 1.3
HVLA-SM After 6 WeeksLumbar-spine Stiffness (LSS)LSS - Palpatory - GSV (N/mm)1.9 N/mmStandard Deviation 1.1
HVLA-SM After 6 WeeksLumbar-spine Stiffness (LSS)LSS - Hand-held - GSV (N/mm)2.1 N/mmStandard Deviation 1.3
HVLA-SM After 6 WeeksLumbar-spine Stiffness (LSS)LSS - Hand-held - GS (N/mm) at L37.6 N/mmStandard Deviation 2.2
Primary

Lumbar-spine Stiffness (LSS) - Normalized Global Stiffness Variation

LSS contains 2 variables: Palpatory and Handheld device - normalized global stiffness variation (nGSV, unitless). LSS Interpretation: The values of the outcome depend on testing procedure, instruction to participants, and equipment. Currently there is no consensus regarding what value is higher than normal, normal, lower than normal.

Time frame: Baseline, 2 weeks, 6 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Experimental: HVLA-SMLumbar-spine Stiffness (LSS) - Normalized Global Stiffness VariationLSS - Palpatory - nGSV0.5 unitlessStandard Deviation 0.2
Experimental: HVLA-SMLumbar-spine Stiffness (LSS) - Normalized Global Stiffness VariationLSS - Hand-held - nGSV0.3 unitlessStandard Deviation 0.1
HVLA-SM After 2 WeeksLumbar-spine Stiffness (LSS) - Normalized Global Stiffness VariationLSS - Palpatory - nGSV0.5 unitlessStandard Deviation 0.2
HVLA-SM After 2 WeeksLumbar-spine Stiffness (LSS) - Normalized Global Stiffness VariationLSS - Hand-held - nGSV0.3 unitlessStandard Deviation 0.1
HVLA-SM After 6 WeeksLumbar-spine Stiffness (LSS) - Normalized Global Stiffness VariationLSS - Palpatory - nGSV0.5 unitlessStandard Deviation 0.2
HVLA-SM After 6 WeeksLumbar-spine Stiffness (LSS) - Normalized Global Stiffness VariationLSS - Hand-held - nGSV0.3 unitlessStandard Deviation 0.1
Primary

Patient-Centered Outcome Measurement Mean Change After 6 Weeks (VAS, RMDQ)

VAS - Visual Analog Scale - Scale: 0-100 mm (anchors: 0 mm = No Pain, 100 mm = Worst Imaginable Pain). VAS Interpretation: A higher score indicates greater pain intensity. In this study, improvement of 30% from the baseline value was considered clinically significant. RMDQ - Roland Morris disability questionnaire - Scale: 0 (no disability) to 24 (maximum disability). RMDQ Interpretation: Greater levels of disability are reflected by higher scores. In this study, improvement of 30% from the baseline value was considered clinically significant.

Time frame: Baseline to 6 weeks

Population: 82 and 68 participants completed at baseline and after 6 weeks, respectively. Data from all participants (n=82) were used in statistical analysis. The reported data represents the mean change from baseline to week 6.

ArmMeasureGroupValue (MEAN)
Experimental: HVLA-SMPatient-Centered Outcome Measurement Mean Change After 6 Weeks (VAS, RMDQ)Mean Reduction in VAS score (mm)20.1 units on a scale (see description above)
Experimental: HVLA-SMPatient-Centered Outcome Measurement Mean Change After 6 Weeks (VAS, RMDQ)Mean Reduction in RMDQ score4.8 units on a scale (see description above)
Secondary

Bothersomeness

Question asked of participants: During the past week, how bothersome have each of the following symptoms been? The bothersomeness questionnaire contains two items: a) low back pain & b) leg pain (sciatica). Scale: 0-10 (anchors: 0 = Not at all bothersome, 10 = Extremely bothersome)

Time frame: Baseline, 2 weeks, 6 weeks

Population: Note: 82, 71 and 68 participants completed at baseline, after 2 weeks and after 6 weeks, respectively. Number of observations made at the three time points were 82, 70, and 68, respectively.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental: HVLA-SMBothersomenessLow Back Pain6.18 units on a scaleStandard Deviation 1.93
Experimental: HVLA-SMBothersomenessLeg Pain (Sciatica)3.29 units on a scaleStandard Deviation 3.18
HVLA-SM After 2 WeeksBothersomenessLow Back Pain4.80 units on a scaleStandard Deviation 2.14
HVLA-SM After 2 WeeksBothersomenessLeg Pain (Sciatica)2.61 units on a scaleStandard Deviation 2.91
HVLA-SM After 6 WeeksBothersomenessLow Back Pain3.63 units on a scaleStandard Deviation 2.3
HVLA-SM After 6 WeeksBothersomenessLeg Pain (Sciatica)1.94 units on a scaleStandard Deviation 2.68
Secondary

Kinetic Measure - Spinal Segment Load (SSL) Force

SSL\* contains variables: maximum amplitude (Newton) during preload and peak thrust force in anterior-posterior (X), side-to-side (Y), head-to-toe direction (Z) and combined force (C). \*Interpretation: the purpose of the outcomes is to quantify force-time profile of SM. The values of the outcome depend on the doctor who delivers SM, location and direction of SM, participant body position, and equipment. Currently there is no consensus regarding what value is higher than normal, normal, or lower than normal. Sign convention: because patient position would affect the sign of some measurements, the right side up position was used as the reference position (i.e., the affected measurements assessed in the left side up position had their sign inverted) in order to calculate mean and SD. The value reported is the change from baseline to week 6.

Time frame: 6 weeks

Population: Note: 82, 71 and 68 participants completed at baseline, after 2 weeks and after 6 weeks, respectively, and a total of 593 SM was delivered during visits 1, 5, and 12. The number of observations for individual measures is lower than the total number of analyzable SM (n=575) due to missing data in corresponding components.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental: HVLA-SMKinetic Measure - Spinal Segment Load (SSL) ForcePreload force (N)-56.5 Newton (N)Standard Deviation 87.2
Experimental: HVLA-SMKinetic Measure - Spinal Segment Load (SSL) ForcePeak thrust force (N)-128.3 Newton (N)Standard Deviation 163.4
HVLA-SM After 2 WeeksKinetic Measure - Spinal Segment Load (SSL) ForcePeak thrust force (N)-172.3 Newton (N)Standard Deviation 141.9
HVLA-SM After 2 WeeksKinetic Measure - Spinal Segment Load (SSL) ForcePreload force (N)-67.0 Newton (N)Standard Deviation 55
HVLA-SM After 6 WeeksKinetic Measure - Spinal Segment Load (SSL) ForcePeak thrust force (N)-276.4 Newton (N)Standard Deviation 137.1
HVLA-SM After 6 WeeksKinetic Measure - Spinal Segment Load (SSL) ForcePreload force (N)-117.2 Newton (N)Standard Deviation 59.4
CombinedKinetic Measure - Spinal Segment Load (SSL) ForcePeak thrust force (N)385.1 Newton (N)Standard Deviation 169.5
CombinedKinetic Measure - Spinal Segment Load (SSL) ForcePreload force (N)170.3 Newton (N)Standard Deviation 64.9
Secondary

Kinetic Measure - Spinal Segment Load (SSL) Moment

SSL\* contains variables: maximum amplitude (Newton\*Meter for moment) during preload and peak thrust force in anterior-posterior (X), side-to-side (Y), head-to-toe direction (Z) and combined force (C). \*Interpretation: the purpose of the outcomes is to quantify force-time profile of SM. The values of the outcome depend on the doctor who delivers SM, location and direction of SM, participant body position, and equipment. Currently there is no consensus regarding what value is higher than normal, normal, or lower than normal. Sign convention: because patient position would affect the sign of some measurements, the right side up position was used as the reference position (i.e., the affected measurements assessed in the left side up position had their sign inverted) in order to calculate mean and SD. The value reported is the change from baseline to week 6.

Time frame: 6 weeks

Population: Note: 82, 71 and 68 participants completed at baseline, after 2 weeks and after 6 weeks, respectively, and a total of 593 SM was delivered during visits 1, 5, and 12. The number of observations for individual measures is lower than the total number of analyzable SM (n=575) due to missing data in corresponding components.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental: HVLA-SMKinetic Measure - Spinal Segment Load (SSL) MomentPeak thrust moment (N*M)31.0 Newton*MeterStandard Deviation 46
Experimental: HVLA-SMKinetic Measure - Spinal Segment Load (SSL) MomentPreload moment (N*M)19.8 Newton*MeterStandard Deviation 23.4
HVLA-SM After 2 WeeksKinetic Measure - Spinal Segment Load (SSL) MomentPreload moment (N*M)-1.0 Newton*MeterStandard Deviation 19.4
HVLA-SM After 2 WeeksKinetic Measure - Spinal Segment Load (SSL) MomentPeak thrust moment (N*M)-3.4 Newton*MeterStandard Deviation 39.9
HVLA-SM After 6 WeeksKinetic Measure - Spinal Segment Load (SSL) MomentPeak thrust moment (N*M)-76.0 Newton*MeterStandard Deviation 42.2
HVLA-SM After 6 WeeksKinetic Measure - Spinal Segment Load (SSL) MomentPreload moment (N*M)-45.4 Newton*MeterStandard Deviation 29.4
CombinedKinetic Measure - Spinal Segment Load (SSL) MomentPeak thrust moment (N*M)99.5 Newton*MeterStandard Deviation 41.9
CombinedKinetic Measure - Spinal Segment Load (SSL) MomentPreload moment (N*M)58.5 Newton*MeterStandard Deviation 27.8
Secondary

Kinetic Measure - Spinal Segment Load (SSL) Rate of Loading for Force

SSL\* contains variables: rate of loading for force in anterior-posterior (X), side-to-side (Y), head-to-toe direction (Z) and combined force (C). \*Interpretation: the purpose of the outcomes is to quantify force-time profile of SM. The values of the outcome depend on the doctor who delivers SM, location and direction of SM, participant body position, and equipment. Currently there is no consensus regarding what value is higher than normal, normal, or lower than normal. Sign convention: because patient position would affect the sign of some measurements, the right side up position was used as the reference position (i.e., the affected measurements assessed in the left side up position had their sign inverted) in order to calculate mean and SD. The value reported is the change from baseline to week 6.

Time frame: 6 weeks

Population: Note: 82, 71 and 68 participants completed at baseline, after 2 weeks and after 6 weeks, respectively, and a total of 593 SM was delivered during visits 1, 5, and 12. The number of observations for individual measures is lower than the total number of analyzable SM (n=575) due to missing data in corresponding components.

ArmMeasureValue (MEAN)Dispersion
Experimental: HVLA-SMKinetic Measure - Spinal Segment Load (SSL) Rate of Loading for Force-599.2 Newton/secondStandard Deviation 897.1
HVLA-SM After 2 WeeksKinetic Measure - Spinal Segment Load (SSL) Rate of Loading for Force-598.1 Newton/secondStandard Deviation 668.8
HVLA-SM After 6 WeeksKinetic Measure - Spinal Segment Load (SSL) Rate of Loading for Force-1145.2 Newton/secondStandard Deviation 713.6
CombinedKinetic Measure - Spinal Segment Load (SSL) Rate of Loading for Force1537.5 Newton/secondStandard Deviation 955.4
Secondary

Kinetic Measure - Spinal Segment Load (SSL) Rate of Loading for Moment

SSL\* contains variables: rate of loading for moment in anterior-posterior (X), side-to-side (Y), head-to-toe direction (Z) and combined force (C). \*Interpretation: the purpose of the outcomes is to quantify force-time profile of SM. The values of the outcome depend on the doctor who delivers SM, location and direction of SM, participant body position, and equipment. Currently there is no consensus regarding what value is higher than normal, normal, or lower than normal. Sign convention: because patient position would affect the sign of some measurements, the right side up position was used as the reference position (i.e., the affected measurements assessed in the left side up position had their sign inverted) in order to calculate mean and SD. The value reported is the change from baseline to week 6.

Time frame: 6 weeks

Population: Note: 82, 71 and 68 participants completed at baseline, after 2 weeks and after 6 weeks, respectively, and a total of 593 SM was delivered during visits 1, 5, and 12. The number of observations for individual measures is lower than the total number of analyzable SM (n=575) due to missing data in corresponding components.

ArmMeasureValue (MEAN)Dispersion
Experimental: HVLA-SMKinetic Measure - Spinal Segment Load (SSL) Rate of Loading for Moment51.3 Newton*Meters/secondStandard Deviation 201.8
HVLA-SM After 2 WeeksKinetic Measure - Spinal Segment Load (SSL) Rate of Loading for Moment-40.4 Newton*Meters/secondStandard Deviation 183.7
HVLA-SM After 6 WeeksKinetic Measure - Spinal Segment Load (SSL) Rate of Loading for Moment-210.2 Newton*Meters/secondStandard Deviation 159
CombinedKinetic Measure - Spinal Segment Load (SSL) Rate of Loading for Moment275.2 Newton*Meters/secondStandard Deviation 194.9
Secondary

PROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status Scale

1\) The questionnaire contains 7 PROMIS-29 specific items: Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction with Participation in Social Role (anchors: 1= 'Not at all', 5= 'Very much', higher score is worse). Each PROMIS-29 specific item is reported in raw score (4-20) and scored in T-score (T), which rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10 for a population. On the T-score metric & interpretation: * A score of 40 is one SD lower than the mean of the reference population. * A score of 60 is one SD higher than the mean of the reference population. * For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured.

Time frame: Baseline, 2 weeks, 6 weeks

Population: Note: 82, 71 and 68 participants completed at baseline, after 2 weeks and after 6 weeks, respectively. Number of observations made at the three time points were 82, 70, and 68, respectively.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental: HVLA-SMPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP-29 - Pain Interference60.26 T-scoreStandard Deviation 5.7
Experimental: HVLA-SMPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29- Sleep Disturbance52.23 T-scoreStandard Deviation 3.13
Experimental: HVLA-SMPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Depression47.02 T-scoreStandard Deviation 7.78
Experimental: HVLA-SMPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Satisfaction w/ Participation in Social Role45.45 T-scoreStandard Deviation 6.84
Experimental: HVLA-SMPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Anxiety49.18 T-scoreStandard Deviation 8.87
Experimental: HVLA-SMPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Fatigue53.72 T-scoreStandard Deviation 8.19
Experimental: HVLA-SMPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Physical Function33.31 T-scoreStandard Deviation 3.93
HVLA-SM After 2 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Anxiety47.93 T-scoreStandard Deviation 7.87
HVLA-SM After 2 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Physical Function32.29 T-scoreStandard Deviation 3.84
HVLA-SM After 2 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29- Sleep Disturbance51.11 T-scoreStandard Deviation 3.23
HVLA-SM After 2 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Fatigue51.93 T-scoreStandard Deviation 7.84
HVLA-SM After 2 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP-29 - Pain Interference57.78 T-scoreStandard Deviation 6.37
HVLA-SM After 2 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Satisfaction w/ Participation in Social Role46.51 T-scoreStandard Deviation 6.75
HVLA-SM After 2 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Depression45.97 T-scoreStandard Deviation 7.07
HVLA-SM After 6 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Satisfaction w/ Participation in Social Role49.75 T-scoreStandard Deviation 7.71
HVLA-SM After 6 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Anxiety46.58 T-scoreStandard Deviation 7.78
HVLA-SM After 6 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Depression44.38 T-scoreStandard Deviation 6.06
HVLA-SM After 6 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP-29 - Pain Interference55.12 T-scoreStandard Deviation 7.52
HVLA-SM After 6 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Physical Function30.07 T-scoreStandard Deviation 3.97
HVLA-SM After 6 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29- Sleep Disturbance51.79 T-scoreStandard Deviation 3.1
HVLA-SM After 6 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: General Health Status ScaleP29 - Fatigue50.09 T-scoreStandard Deviation 7.87
Secondary

PROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: Global Item, Pain NRS

1\) The PROMIS questionnaire contains 1 PROMIS global item: Pain NRS, Scale: 0-10 (anchors: 0 = No Pain, 10 = Worst Imaginable Pain, higher score is worse). The PROMIS global item is not scored but reported in raw score.

Time frame: Baseline, 2 weeks, 6 weeks

Population: Note: 82, 71 and 68 participants completed at baseline, after 2 weeks and after 6 weeks, respectively. Number of observations made at the three time points were 82, 70, and 68, respectively.

ArmMeasureValue (MEAN)Dispersion
Experimental: HVLA-SMPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: Global Item, Pain NRS5.57 units on a scaleStandard Deviation 1.63
HVLA-SM After 2 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: Global Item, Pain NRS4.46 units on a scaleStandard Deviation 1.95
HVLA-SM After 6 WeeksPROMIS-29 - Patient Reported Outcomes Measurement Information Scale-29: Global Item, Pain NRS3.59 units on a scaleStandard Deviation 2.18

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026